Abstract
The third generation tyrosine kinase inhibitor (TKI) ponatinib extends the therapeutic armamentarium for the management of nilotinib- and dasatinib-refractory chronic myeloid leukemia (CML).1 Vascular complications, especially arterial events, have been associated with nilotinib and ponatinib only and are an emerging issue when using these two TKIs in CML.2, 3, 4, 5
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
